Vaccine

Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for…

3 years ago

TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference

FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…

3 years ago

Press Release: Evolution of the Board of Directors

Evolution of the Board of Directors Paris, September 5, 2022. The Board of Directors of Sanofi met on September 2,…

3 years ago

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),…

3 years ago

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical…

3 years ago

Blue Water Vaccines to Present at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY

CINCINNATI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a…

3 years ago

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:…

3 years ago

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent…

3 years ago

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter…

3 years ago